![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Details:
GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and safer treatment regimen.
Lead Product(s): Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area: Endocrinology Product Name: GMRx4
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: CUREator
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 20, 2022
Details:
GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021